Prices delayed by at least 15 minutes | Print


ROCHE GS (ROG)

Sell: 229.6 CHF|Buy: 229.7 CHF|Change: 2.95 (1.30%)

Open 

226.1 CHF


Previous close 

226.75 CHF


Trade high 

230.05 CHF


Volume 

1,443,820


Year high 

293.55 CHF


Year low 

222.75 CHF


Dividend yield 

4.23%


Market capitalisation 

183.13 bn CHF


P/E ratio 

15.85


ISIN 

CH0012032048


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 28/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
ROCHE GS+ 1.30
More...

Company profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.